FDA to Host Town Hall on Final Guidance for Human Factors Information in Medical Device Marketing Submissions on June 1, 2026

FDA to Host Town Hall on Final Guidance for Human Factors Information in Medical Device Marketing Submissions

Source institution: FDA | Original date: June 1, 2026 | Published: July 8, 2026, 09:00 | Source link: https://www.fda.gov/medical-devices/medical-devices-news-and-events/town-hall-content-human-factors-information-medical-device-marketing-submissions-final-guidance

The FDA has released information about a Town Hall event related to its final guidance on human factors information in medical device marketing submissions, reminding companies to prepare more robust evidence on human-machine interaction, usability engineering and use-related risk control.

Full Translated Core Content

According to the FDA event page, the agency will hold a dedicated Town Hall on the final guidance on human factors information in medical device marketing submissions. Human factors information focuses on risks arising in real-world use from the combination of users, interfaces, tasks, training, warnings and use scenarios. It is particularly relevant to home-use devices, emergency devices, infusion devices, software interfaces and other products with a higher risk of misuse.

In FDA marketing submissions, human factors documentation generally needs to explain how critical tasks are identified, how potential use errors are analyzed, how the user interface and labeling mitigate risks, and how validation testing covers target users and use environments. Companies cannot replace human factors engineering evidence solely with instructions for use or training materials.

For companies preparing 510(k), De Novo or PMA submissions, human factors information should be linked with risk management, labeling and instructions for use, software interfaces, clinical use workflows and postmarket complaint data. The higher the risk, the greater the home-use setting, the more complex the operation or the greater the reliance on software interfaces, the earlier human factors validation should be planned.

AIMEILI Regulatory Interpretation

AIMEILI Regulatory Department believes that the updates related to software, artificial intelligence and human factors together indicate a trend: regulators are moving medical device software review from “feature description review” to “real-world use scenario review.” Companies cannot only prove that software runs, that algorithm accuracy is high, or that the interface appears clear; they must also prove that the product can be used safely, stably and explainably by target users in target scenarios and at target risk levels.

For SaMD, artificial-intelligence-assisted diagnosis, clinical decision support, remote monitoring and products with complex user interfaces, the registration dossier should cover intended use, inputs and outputs, user roles, algorithm boundaries, data representativeness, performance validation, clinical evidence, cybersecurity, software lifecycle, human factors validation and postmarket version management. For artificial intelligence products in particular, regulatory focus is often on data bias, applicable populations, clinical scenarios, model changes and interpretation of results, rather than the degree of “intelligence” promoted by the company.

AIMEILI recommends that companies establish a “software medical device evidence package” that places algorithm description, data governance, performance validation, human factors engineering, cybersecurity, risk management, clinical evaluation and version control within a single document system. In this way, when entering markets such as FDA, PMDA, MFDS, HSA and EU MDR, companies can quickly adapt to different regulatory requirements rather than preparing supplementary materials on an ad hoc basis for each country.

Business Impact

Human factors documentation cannot be replaced by clear instructions. Companies need to demonstrate that critical tasks have been identified, potential use errors have undergone risk analysis, and the user interface, alarms, labeling, training and validation testing can reduce use-related risk. If a product is planned for an FDA marketing submission, human factors engineering activities should be designed in parallel during research and validation, not added at the registration stage.

Compliance Actions for Companies to Consider

• Confirm whether the update affects existing registration pathways, certificate maintenance or postmarket obligations.
• Check the target country’s technical file, labeling and instructions for use, quality management system and local responsible entity arrangements.
• Establish change impact assessments and regulatory update tracking records for marketed products.
• Where necessary, archive the official source text, regulatory interpretation and internal action items for future audits and project reviews.